Good manufacturing practices for complementary medicinesTGA Australia
This presentation provides an overview of GMP clearance application process, the TGA compliance risk framework, major deficiencies and manufacturing quality challenges.
1) The TGA inspection process for manufacturers faces challenges from high workloads, incomplete sponsor applications, and an increase in identified manufacturing deficiencies requiring follow-up.
2) The TGA and sponsors can both take actions to address these challenges, such as sponsors notifying the TGA early of changes to minimize wasted inspection planning. The TGA is exploring process improvements and incentives to reduce workloads.
3) Common manufacturing deficiencies identified by TGA inspectors include inadequate quality management systems, personnel training, equipment and facility qualification, process validation, and quality control testing. Addressing these deficiencies requires effective manufacturer corrective actions.
PIC/S Guide to GMP PE009-13 - Key changes to Annex 15 - Qualification and val...TGA Australia
The TGA has now legislated version 13 of the PIC/S guide to GMP for medicinal products with a transition period for implementation ending at the end of 2018. Some of the biggest changes in this version were in Annex 15 – Qualification and Validation. This has an impact across all areas in including small to medium sized manufacturers as well as sponsors who need to understand the impact in their supply chain including contract manufacturing and storage and transportation.
This document provides guidance on preparing a site master file (SMF) for pharmaceutical manufacturing sites. It outlines the key information that should be included in an SMF, such as descriptions of quality management systems, personnel, facilities, equipment, production, quality control, distribution, and procedures for complaints and recalls. The SMF is intended to provide regulatory authorities with information on GMP compliance during inspections.
Good manufacturing practices for complementary medicinesTGA Australia
This presentation provides an overview of GMP clearance application process, the TGA compliance risk framework, major deficiencies and manufacturing quality challenges.
1) The TGA inspection process for manufacturers faces challenges from high workloads, incomplete sponsor applications, and an increase in identified manufacturing deficiencies requiring follow-up.
2) The TGA and sponsors can both take actions to address these challenges, such as sponsors notifying the TGA early of changes to minimize wasted inspection planning. The TGA is exploring process improvements and incentives to reduce workloads.
3) Common manufacturing deficiencies identified by TGA inspectors include inadequate quality management systems, personnel training, equipment and facility qualification, process validation, and quality control testing. Addressing these deficiencies requires effective manufacturer corrective actions.
PIC/S Guide to GMP PE009-13 - Key changes to Annex 15 - Qualification and val...TGA Australia
The TGA has now legislated version 13 of the PIC/S guide to GMP for medicinal products with a transition period for implementation ending at the end of 2018. Some of the biggest changes in this version were in Annex 15 – Qualification and Validation. This has an impact across all areas in including small to medium sized manufacturers as well as sponsors who need to understand the impact in their supply chain including contract manufacturing and storage and transportation.
This document provides guidance on preparing a site master file (SMF) for pharmaceutical manufacturing sites. It outlines the key information that should be included in an SMF, such as descriptions of quality management systems, personnel, facilities, equipment, production, quality control, distribution, and procedures for complaints and recalls. The SMF is intended to provide regulatory authorities with information on GMP compliance during inspections.
TGA presentation: PICS Guide for GMP and Data Integrity relating to microbiol...TGA Australia
An overview of regulatory requirements introduced as part of the new PIC/s PE009-13 Guide to Good Manufacturing Practice, specifically outlining impact on micro laboratories. Also, a summary of the new PI041-1 Data Integrity Guidance will be provided with a particular focus of Data Integrity in the laboratory
On January 22, 2013 the China SFDA published a Good Supply Practice guidance that will be implemented on June 1, 2013. Businesses will have a 3 year period to phase in the requirements and if this has not been accomplished by the deadline in 2016 they will be required to cease their activities. This is another demonstration that China is working diligently to upgrade the quality of their pharmaceutical manufacture and distribution networks.
The guidance significantly increases the requirements for Quality Management. The relevant chapters include: General Provisions, Drug Wholesale Quality Management, Drug Retail Quality Management, and Supplementary provisions. Significant emphasis is placed on the standards to be implemented for computerized hardware and software systems. The use of controlled computerized systems is intended to both be an aid in protection of drug quality but will also serve as a barrier to entry into this part of the pharmaceutical business.
Quality & compliance excellence in pharmaceuticalsAnvita Bharati
Quality can be defined in several ways including conformance to specifications, fitness for use, and value for price paid. It is judged based on factors like performance, reliability, and support services provided. Pharmaceutical products have higher quality standards and more regulations compared to consumer goods due to their intended use and potential risks. Ensuring compliance with various quality guidelines is important for patient safety and involves establishing quality systems, policies, procedures, documentation, and ongoing assessments like audits and corrective actions. Non-compliance can result in issues like complaints, recalls, and regulatory actions.
As you know, pharma compliance is a critical issue, particularly in China. The Chinese government’s recent crackdowns on the business practices of various pharmaceutical companies have sent shockwaves throughout the industry and the price to pay for non-compliance is exceedingly high, with massive revenue losses and irreclaimable reputational damages
To address this pertinent issue, IBC Asia is convening the forthcoming Pharma Compliance Summit
(Mar 2015) in Shanghai, China. Set to be an informative and insightful event, this conference will prepare participants in dealing with the latest legal compliance landmines and equip them with an in-depth understanding of how to mitigate non- compliance risks at every part of the pharma value chain.
Top companies will share best practices of internal compliance programs and third party due diligence strategies; Gain these exclusive insights and incorporate them into their own company, reaping maximum benefits.
Your expert speaker faculty includes:
• Leon Wang, Vice President, AstraZeneca China
• Heike Deters, Head of Compliance, Bayer Healthcare China
• Dr Wang Xianlin, Member, Expert Advisory Group of Anti-Monopoly Commission, State Council People’s Republic of China
• Maija Burtmanis, Regional Legal & Compliance Director JAPAC, AbbVie
• Gareth Lee, General Counsel & Head of Compliance APAC, Allergan
• Cristopher Landrito, Regional Compliance Manager APAC, Merck
• David Shen, General Counsel & VP Legal, AstraZeneca China
• Dr Wu Ke, President, Shanghai BravoBio
• Alejandro Castro, Regional Audit Manager Asia Pacific, Novartis
• Linda Ling, Senior Healthcare Compliance Manager, OTC China, Johnson & Johnson
http://www.pharmacompliance-china.com
The document provides guidance on technology transfer between pharmaceutical manufacturing sites. It discusses that technology transfer requires a documented, planned approach with trained personnel and quality systems. A successful transfer involves the sending unit providing documentation to the receiving unit, conducting training, and jointly executing a transfer protocol. The receiving unit must demonstrate it can routinely reproduce the product or process to specifications. The guidance addresses general principles, planning, information to be transferred for active pharmaceutical ingredients and excipients, process validation, and assessing a successful transfer.
This document provides guidance on validation and qualification principles from the World Health Organization (WHO). It discusses the need for validation and qualification activities to ensure product quality, safety, and efficacy throughout the product lifecycle. Key aspects covered include definitions of validation terms, approaches to validation planning, and documentation requirements such as a validation master plan and protocols.
This document discusses guidelines for assessing elemental impurities in pharmaceutical products according to ICH Q3D. It describes a risk-based approach to evaluating potential sources of elemental impurities from drug substances, excipients, equipment and processing aids. Specific approaches are provided for assessing impurities from metal catalysts, water sources, and packaging materials. The presentation emphasizes controlling impurities through an understanding of manufacturing processes and applying appropriate testing and control strategies.
Annual product reviews are conducted annually to assess the quality of drug products and determine if any changes need to be made to product specifications, manufacturing processes, or quality control procedures. The review evaluates analytical data, inspection results, batch failures, complaints, recalls, deviations, stability monitoring results, and corrective actions to verify process consistency and identify quality trends over time. The goal is to continually improve product quality and manufacturing processes.
Presentation: TGA manufacturing principles update - Adoption of PIC/S Guide t...TGA Australia
TGA is adopting updates to the PIC/S Guide to GMP including PE009-13 and future revisions such as PE009-14. Key points include:
- PE009-13 was adopted on January 1, 2018 with a 12 month transition period for industry to comply.
- Future revisions will address additional chapters and annexes to further clarify requirements.
- TGA plays an active role in updating PIC/S GMP guidance to ensure risks are addressed and GMP keeps pace with innovation.
- Adopting international standards supports TGA's mutual recognition agreements and provides assurance in international markets.
Quality management systems for medical, pharmaceutical,Khalizan Halid
This presentation provides an overview of the role that a computerized quality management system plays in a manufacturer practising Good Manufacturing Practices and compares it's complimentary functions against an Enterprise Resource Planning System
Second Party Audit and External Third Party AuditShantanuThakre3
Second Party Audit:- Second-party audit is when a company performs an audit of a supplier to ensure that they are meeting the requirements specified in the contract.
External Third Party Audit:-
A third-party audit occurs when a company has decided that they want to create a Quality Management System (QMS) that conforms to a standard set of requirements, such as ISO 9001 and hire an independent auditing company to perform an audit to verify that the company has succeeded in meeting these standards.
Quality Systems Approach to Pharmaceutical cGMPReddy N
This guidance provides a quality systems model that aligns with CGMP regulations to help manufacturers implement modern quality systems approaches. It describes key quality systems concepts such as quality by design, quality risk management, corrective and preventive action, and change control. The guidance explains how the quality unit's responsibilities correlate with quality assurance and quality control functions. It presents a quality systems model organized into sections for management responsibilities, resources, manufacturing operations, and evaluation activities. The model identifies how each quality systems element aligns with specific CGMP regulations.
The document discusses quality management systems (QMS) and good manufacturing practices (GMP) and their benefits for businesses. It provides an overview of the key elements of a QMS and explains that a QMS establishes procedures and processes to ensure quality control across all aspects of a business. It then describes GMP guidelines which outline manufacturing and testing standards for pharmaceuticals and medical devices to ensure product quality and compliance. The document notes that many countries have legislation requiring companies to follow GMP procedures.
This is a presentation based on ICH Q10, Pharmaceutical Quality System, It was shared recently with participants of a training session arranged by Ingrope Information Services karachi at marriot Hotel. I am uploading for the benefits of all pharma colleagues, specially the junior ones.
A primary mission of the Food and Drug Administration is to conduct comprehensive regulatory coverage of all aspects of production and distribution of drugs and drug products to assure that such products meet the 501(a)(2)(B) requirements of the Act. FDA has developed two basic strategies:
. 1) evaluating through factory inspections, including the collection and analysis of associated samples, the conditions and practices under which drugs and drug products are manufactured, packed, tested and held, and
. 2) monitoring the quality of drugs and drug products through surveillance activities such as sampling and analyzing products in distribution.
FDA compliance program “ Drug Manufacturing Inpsections” (7356.002) is designed to provide guidance for implementing the first strategy. Products from production and distribution facilities covered under this program are consistently of acceptable quality if the firm is operating in a state of control.
The inspectional guidance in this program is structured to provide for efficient use of resources devoted to routine surveillance coverage, recognizing that in-depth coverage of all systems and all processes is not feasible for all firms on a biennial basis. It also provides for follow-up compliance coverage as needed.
“Drug Regulations” has prepared a summary from the compliance programme and is given below in the presentation.
Documentation with respect to release of finished pharmaceutical productMadhuraNewrekar
Documentation is a crucial part of the quality assurance system and is needed in every aspect of pharmaceutical manufacturing. Important documentation with respect to final product release in pharmaceutical industry is explained in brief.
This presentation describes the principles of qualification and validation which are applicable to the facilities, equipment, utilities and processes used for the manufacture of medicinal products. It is a GMP requirement that manufacturer’s control the critical aspects of their particular operations through qualification and validation over the life cycle of the product and process. Any planned changes to the facilities, equipment, utilities and processes, which may affect the quality of the product, should be formally documented and the impact on the validated status or control strategy assessed.
This document outlines quality system requirements for national pharmaceutical inspection services that conduct GMP inspections of manufacturers and wholesale distributors. It specifies that inspection services must establish a quality manual, administrative structure, documentation control, records management, inspection procedures and resources, internal audits, quality improvement processes, and procedures for handling complaints and recalls. The goal is to achieve consistency in inspection standards across national authorities to facilitate mutual recognition and confidence between inspection services.
This presentation provides an outline to illegal products and what can be done including collaboration both domestically and internationally while ensuring quality is considered.
The TGA Pharmacovigilance Inspection Pilot Program: 2015-2016TGA Australia
Firsthand overview of the TGA's Pharmacovigilance Inspection programme from the perspective of both the TGA and companies that have participated in the 'Pilot Inspection Programme'.
TGA presentation: PICS Guide for GMP and Data Integrity relating to microbiol...TGA Australia
An overview of regulatory requirements introduced as part of the new PIC/s PE009-13 Guide to Good Manufacturing Practice, specifically outlining impact on micro laboratories. Also, a summary of the new PI041-1 Data Integrity Guidance will be provided with a particular focus of Data Integrity in the laboratory
On January 22, 2013 the China SFDA published a Good Supply Practice guidance that will be implemented on June 1, 2013. Businesses will have a 3 year period to phase in the requirements and if this has not been accomplished by the deadline in 2016 they will be required to cease their activities. This is another demonstration that China is working diligently to upgrade the quality of their pharmaceutical manufacture and distribution networks.
The guidance significantly increases the requirements for Quality Management. The relevant chapters include: General Provisions, Drug Wholesale Quality Management, Drug Retail Quality Management, and Supplementary provisions. Significant emphasis is placed on the standards to be implemented for computerized hardware and software systems. The use of controlled computerized systems is intended to both be an aid in protection of drug quality but will also serve as a barrier to entry into this part of the pharmaceutical business.
Quality & compliance excellence in pharmaceuticalsAnvita Bharati
Quality can be defined in several ways including conformance to specifications, fitness for use, and value for price paid. It is judged based on factors like performance, reliability, and support services provided. Pharmaceutical products have higher quality standards and more regulations compared to consumer goods due to their intended use and potential risks. Ensuring compliance with various quality guidelines is important for patient safety and involves establishing quality systems, policies, procedures, documentation, and ongoing assessments like audits and corrective actions. Non-compliance can result in issues like complaints, recalls, and regulatory actions.
As you know, pharma compliance is a critical issue, particularly in China. The Chinese government’s recent crackdowns on the business practices of various pharmaceutical companies have sent shockwaves throughout the industry and the price to pay for non-compliance is exceedingly high, with massive revenue losses and irreclaimable reputational damages
To address this pertinent issue, IBC Asia is convening the forthcoming Pharma Compliance Summit
(Mar 2015) in Shanghai, China. Set to be an informative and insightful event, this conference will prepare participants in dealing with the latest legal compliance landmines and equip them with an in-depth understanding of how to mitigate non- compliance risks at every part of the pharma value chain.
Top companies will share best practices of internal compliance programs and third party due diligence strategies; Gain these exclusive insights and incorporate them into their own company, reaping maximum benefits.
Your expert speaker faculty includes:
• Leon Wang, Vice President, AstraZeneca China
• Heike Deters, Head of Compliance, Bayer Healthcare China
• Dr Wang Xianlin, Member, Expert Advisory Group of Anti-Monopoly Commission, State Council People’s Republic of China
• Maija Burtmanis, Regional Legal & Compliance Director JAPAC, AbbVie
• Gareth Lee, General Counsel & Head of Compliance APAC, Allergan
• Cristopher Landrito, Regional Compliance Manager APAC, Merck
• David Shen, General Counsel & VP Legal, AstraZeneca China
• Dr Wu Ke, President, Shanghai BravoBio
• Alejandro Castro, Regional Audit Manager Asia Pacific, Novartis
• Linda Ling, Senior Healthcare Compliance Manager, OTC China, Johnson & Johnson
http://www.pharmacompliance-china.com
The document provides guidance on technology transfer between pharmaceutical manufacturing sites. It discusses that technology transfer requires a documented, planned approach with trained personnel and quality systems. A successful transfer involves the sending unit providing documentation to the receiving unit, conducting training, and jointly executing a transfer protocol. The receiving unit must demonstrate it can routinely reproduce the product or process to specifications. The guidance addresses general principles, planning, information to be transferred for active pharmaceutical ingredients and excipients, process validation, and assessing a successful transfer.
This document provides guidance on validation and qualification principles from the World Health Organization (WHO). It discusses the need for validation and qualification activities to ensure product quality, safety, and efficacy throughout the product lifecycle. Key aspects covered include definitions of validation terms, approaches to validation planning, and documentation requirements such as a validation master plan and protocols.
This document discusses guidelines for assessing elemental impurities in pharmaceutical products according to ICH Q3D. It describes a risk-based approach to evaluating potential sources of elemental impurities from drug substances, excipients, equipment and processing aids. Specific approaches are provided for assessing impurities from metal catalysts, water sources, and packaging materials. The presentation emphasizes controlling impurities through an understanding of manufacturing processes and applying appropriate testing and control strategies.
Annual product reviews are conducted annually to assess the quality of drug products and determine if any changes need to be made to product specifications, manufacturing processes, or quality control procedures. The review evaluates analytical data, inspection results, batch failures, complaints, recalls, deviations, stability monitoring results, and corrective actions to verify process consistency and identify quality trends over time. The goal is to continually improve product quality and manufacturing processes.
Presentation: TGA manufacturing principles update - Adoption of PIC/S Guide t...TGA Australia
TGA is adopting updates to the PIC/S Guide to GMP including PE009-13 and future revisions such as PE009-14. Key points include:
- PE009-13 was adopted on January 1, 2018 with a 12 month transition period for industry to comply.
- Future revisions will address additional chapters and annexes to further clarify requirements.
- TGA plays an active role in updating PIC/S GMP guidance to ensure risks are addressed and GMP keeps pace with innovation.
- Adopting international standards supports TGA's mutual recognition agreements and provides assurance in international markets.
Quality management systems for medical, pharmaceutical,Khalizan Halid
This presentation provides an overview of the role that a computerized quality management system plays in a manufacturer practising Good Manufacturing Practices and compares it's complimentary functions against an Enterprise Resource Planning System
Second Party Audit and External Third Party AuditShantanuThakre3
Second Party Audit:- Second-party audit is when a company performs an audit of a supplier to ensure that they are meeting the requirements specified in the contract.
External Third Party Audit:-
A third-party audit occurs when a company has decided that they want to create a Quality Management System (QMS) that conforms to a standard set of requirements, such as ISO 9001 and hire an independent auditing company to perform an audit to verify that the company has succeeded in meeting these standards.
Quality Systems Approach to Pharmaceutical cGMPReddy N
This guidance provides a quality systems model that aligns with CGMP regulations to help manufacturers implement modern quality systems approaches. It describes key quality systems concepts such as quality by design, quality risk management, corrective and preventive action, and change control. The guidance explains how the quality unit's responsibilities correlate with quality assurance and quality control functions. It presents a quality systems model organized into sections for management responsibilities, resources, manufacturing operations, and evaluation activities. The model identifies how each quality systems element aligns with specific CGMP regulations.
The document discusses quality management systems (QMS) and good manufacturing practices (GMP) and their benefits for businesses. It provides an overview of the key elements of a QMS and explains that a QMS establishes procedures and processes to ensure quality control across all aspects of a business. It then describes GMP guidelines which outline manufacturing and testing standards for pharmaceuticals and medical devices to ensure product quality and compliance. The document notes that many countries have legislation requiring companies to follow GMP procedures.
This is a presentation based on ICH Q10, Pharmaceutical Quality System, It was shared recently with participants of a training session arranged by Ingrope Information Services karachi at marriot Hotel. I am uploading for the benefits of all pharma colleagues, specially the junior ones.
A primary mission of the Food and Drug Administration is to conduct comprehensive regulatory coverage of all aspects of production and distribution of drugs and drug products to assure that such products meet the 501(a)(2)(B) requirements of the Act. FDA has developed two basic strategies:
. 1) evaluating through factory inspections, including the collection and analysis of associated samples, the conditions and practices under which drugs and drug products are manufactured, packed, tested and held, and
. 2) monitoring the quality of drugs and drug products through surveillance activities such as sampling and analyzing products in distribution.
FDA compliance program “ Drug Manufacturing Inpsections” (7356.002) is designed to provide guidance for implementing the first strategy. Products from production and distribution facilities covered under this program are consistently of acceptable quality if the firm is operating in a state of control.
The inspectional guidance in this program is structured to provide for efficient use of resources devoted to routine surveillance coverage, recognizing that in-depth coverage of all systems and all processes is not feasible for all firms on a biennial basis. It also provides for follow-up compliance coverage as needed.
“Drug Regulations” has prepared a summary from the compliance programme and is given below in the presentation.
Documentation with respect to release of finished pharmaceutical productMadhuraNewrekar
Documentation is a crucial part of the quality assurance system and is needed in every aspect of pharmaceutical manufacturing. Important documentation with respect to final product release in pharmaceutical industry is explained in brief.
This presentation describes the principles of qualification and validation which are applicable to the facilities, equipment, utilities and processes used for the manufacture of medicinal products. It is a GMP requirement that manufacturer’s control the critical aspects of their particular operations through qualification and validation over the life cycle of the product and process. Any planned changes to the facilities, equipment, utilities and processes, which may affect the quality of the product, should be formally documented and the impact on the validated status or control strategy assessed.
This document outlines quality system requirements for national pharmaceutical inspection services that conduct GMP inspections of manufacturers and wholesale distributors. It specifies that inspection services must establish a quality manual, administrative structure, documentation control, records management, inspection procedures and resources, internal audits, quality improvement processes, and procedures for handling complaints and recalls. The goal is to achieve consistency in inspection standards across national authorities to facilitate mutual recognition and confidence between inspection services.
This presentation provides an outline to illegal products and what can be done including collaboration both domestically and internationally while ensuring quality is considered.
The TGA Pharmacovigilance Inspection Pilot Program: 2015-2016TGA Australia
Firsthand overview of the TGA's Pharmacovigilance Inspection programme from the perspective of both the TGA and companies that have participated in the 'Pilot Inspection Programme'.
The regulation of complementary medicinesTGA Australia
The Therapeutic Goods Administration (TGA) regulates complementary medicines in Australia using a risk-based, two-tiered system. Lower risk listed medicines can be marketed with minimal pre-market evaluation, while higher risk registered medicines require pre-market assessment of quality, safety and efficacy. The TGA oversees post-market monitoring and compliance reviews to ensure that medicines meet regulatory requirements. Guidance materials provide information on evidence requirements and the different pathways for listed and registered complementary medicines.
Pharmacovigilance - a regulator's perspectiveTGA Australia
The document discusses pharmacovigilance from the perspective of the Therapeutic Goods Administration (TGA) in Australia. It provides an overview of the TGA's pharmacovigilance activities, including pre-market risk management plans and post-market adverse event reporting and signal detection. It describes how the TGA monitors the safety of medicines throughout their lifecycle to identify new or unknown risks following approval.
The Therapeutic Goods Administration or TGA is the regulatory body for therapeutic goods in Australia.
The TGA is responsible for conducting assessment and monitoring activities to ensure that therapeutic goods available in Australia are of an acceptable standard.
Regulatory Reform - Are we heading in the right direction?TGA Australia
The document summarizes updates from the Therapeutic Goods Administration (TGA) regarding regulatory reform efforts. Key points include: 1) TGA is restructuring to improve processes; 2) The government aims to improve innovation through regulatory reform while ensuring safety; and 3) TGA is working to streamline complementary medicine processes, international cooperation, manufacturing standards, and labelling reviews. The assistant secretary notes reforms are improving processes under the existing framework while further changes may come from ongoing reviews.
Medicines and Medical Devices Regulation – current developments and future op...TGA Australia
1. The document summarizes recent developments and future options in medicines and medical devices regulation in Australia, as presented by John Skerritt from the Department of Health.
2. Key updates included planned changes to medicines labeling, reviews of programs for orphan drugs and recalls, and a new online system for clinical trial notifications.
3. The presentation also discussed an expert panel review that recommended modernizing approval pathways for new drugs and generics, adopting risk-based approaches, and reforms to schemes for unapproved products.
Presentation Recall of Therapeutic Goods – Overview TGA Australia
This document provides an overview of recalls of therapeutic goods in Australia. It discusses the roles and responsibilities of different parties in coordinating and conducting recalls, including the Recalls Section of the Australian Department of Health, sponsors, manufacturers, and the Therapeutic Goods Administration (TGA). Key points covered include:
- The Uniform Recall Procedure for Therapeutic Goods (URPTG) provides definitions and procedures for different types of recalls and non-recall actions.
- Manufacturers, sponsors and the TGA each have responsibilities in identifying issues, assessing risks, developing communication strategies, and reporting on recall outcomes.
- The TGA reviews recall plans, publishes information on the System of Australian Recall Actions (SARA) database,
This presentation introduces pharmaceutical quality assurance and quality control. It discusses that quality assurance covers all aspects of production from raw materials to finished products. Quality control ensures drugs are safe, effective and consistent. The presentation covers in-process quality control, production processes like blending and milling, and quality control of the storage facility. It also discusses technology transfer requirements for pharmaceutical production like manufacturing instructions, analytical methods and batch records.
Presentation: An Update on post-market regulatory requirementsTGA Australia
Along with implementation of expedited medicine registration pathways TGA has undertaken enhancements to its post-market monitoring of medicines, with a focus on assisting sponsors meet their regulatory requirements. TGA's new Pharmacovigilance Inspection Program (PVIP) involves interviewing sponsors and reviewing documents in order to assess sponsors' level of compliance with pharmacovigilance obligations. Work is also ongoing with sponsors to determine how best to confirm risk management plan (RMP) commitments are being met. This presentation will provide further detail on how TGA is working with and assisting sponsors satisfy their regulatory requirements.
Presentation: Pharmacovigilance requirements inspected and example findingsTGA Australia
Presentations given at the TGA information sessions cover the pharmacovigilance inspection guidelines, preparing for inspections, inspection process, and close out of inspections.
TGA Presentation: What’s happening in regulation?TGA Australia
This presentation provides an overview of the Government's response to the Expert Panel Review of Medicines and Medical Devices, with an emphasis on complementary medicines changes.
The document discusses several ethical issues in forensic pharmacy, including quality assurance and good manufacturing practices in pharmaceutical production. It outlines laws and regulations that manufacturers must follow to ensure drug quality, safety, and efficacy. It also discusses good storage and distribution practices, including maintaining cold chains for temperature-sensitive drugs. The document emphasizes that pharmacists must handle product complaints, recalls, and imports/exports of controlled substances ethically and according to documented procedures to protect patient safety.
Regulatory affairs professionals ensure that pharmaceutical products comply with regulations throughout the development, manufacturing, and marketing processes. They advise internal departments and collect data to submit to regulatory agencies for approvals. Dossiers containing technical documents are submitted for registration. Modules cover administrative information, quality overview, chemistry and manufacturing controls for drug substances and products, preclinical data, and clinical trial results. Regulatory professionals help companies avoid issues by properly managing records, data, and agency requirements.
It is of key importance that the quality and the integrity of the medicinal products are maintained during the entire supply chain from the manufacturer to the patient. Today’s distribution network for medicinal products is increasingly complex and involves many players. The revised guidelines, published today, lay down appropriate tools to assist wholesale distributors in conducting their activities and to prevent falsified medicines from entering the legal supply chain.
The revised guidelines introduce the following changes:
the maintenance of a quality system setting out responsibilities, processes and risk management principles in relation to wholesale activities;
suitable documentation which prevents errors from spoken communication;
sufficient competent personnel to carry out all the tasks for which the wholesale distributor is responsible;
adequate premises, installations and equipment so as to ensure proper storage and distribution of medicinal products;
appropriate management of complaints, returns, suspected falsified medicinal products and recalls;
outsourced activities correctly defined to avoid misunderstandings;
rules for transport in particular to protect medicinal products against breakage, adulteration and theft, and to ensure that temperature conditions are maintained within acceptable limits during transport;
Specific rules for brokers (person involved in activities in relation to the sale or purchase of medicinal products)
Drug Regulations has prepared a presentation summarizing the new GDP requirements for Medicinal Products.
The document compares regulatory frameworks and GMP requirements between the EU and US. Some key differences include:
- EU GMP requirements are outlined in regulations, directives and guides while US requirements are in the CFR which has legal binding force.
- In the EU, the EMA and national competent authorities oversee drug approvals and inspections while in the US the FDA fulfills these roles.
- Process validation approaches have been expanded in the EU to include continuous and hybrid methods in addition to traditional approaches.
- The EU places greater emphasis on quality systems, process monitoring and product quality reviews over the lifetime of the product.
- Collaboration initiatives between the EU and US aim to further harmonize regulations and inspection processes
Pharmacovigilance and complementary medicines - Regulatory requirementsTGA Australia
Presentation on Pharmacovigilance basics – sponsor obligations, Complementary medicine safety – Regulatory perspective and Special considerations for complementary medicine pharmacovigilance
The challenges of regulating direct to consumer digital medical devicesTGA Australia
Presentation on digital medical devices, the role of the regulator, challenges in applying the framework to digital devices, international approaches and what is the TGA doing
Updates from the Pharmacovigilance and Special Access Branch TGA Australia
Presentation on using new sources of data in Pharmacovigilance, Pharmacovigilance Inspection Program (PVIP) update, International collaboration activities, Adverse Event Management System (AEMS)
Q and A
Regulatory updates from the Complementary and OTC Medicines Branch - Listed m...TGA Australia
The document discusses several regulatory reforms for listed medicines in Australia, including:
1. Permitted indications which provide a list of approved health benefit claims for listed medicines and require sponsors to select from this list, improving transparency.
2. An assessed listed pathway which allows pre-market evaluation of efficacy claims, providing access to higher-level health claims.
3. A "TGA assessed" label claim indicating the medicine's efficacy has been evaluated, improving consumer awareness and confidence.
4. Two years of market exclusivity for sponsors who apply for and are approved for new permitted ingredients.
Regulation, ethics and reimbursement of novel biological therapies in Austral...TGA Australia
The document provides an overview of novel biological therapies such as gene therapy, cell therapy, and tissue engineering in Australia. It discusses the regulatory pathways through the Therapeutic Goods Administration (TGA) for approval of these therapies. Clinical trials of novel biological therapies must be submitted through the CTX scheme for approval rather than just notification. Guidelines from the European Medicines Agency are a good resource for requirements for registration and approval of these therapies in Australia. Risks associated with gene therapy include potential for delayed adverse effects, off-target effects, insertional mutagenesis, and immune responses.
Manufacturing Investigational Medicinal Products - Legislative and GMP requir...TGA Australia
Presentation on Legislative requirements, specific risks for IMP manufacturing, manufacturing authorisations, PIC/S Guide to GMP PE009-13 and common issues
Update on regulatory reforms from the Scientific Evaluation BranchTGA Australia
Presentation on the latest on variations, Generic Medicines Reform Program, Human cells and tissue regulation (excluded goods), Faecal Microbiota Transplantation and 2D DataMatrix codes for medicines
Update on regulatory reforms from the Scientific Evaluation BranchTGA Australia
Presentation on the latest on variations, Generic Medicines Reform Program, Human cells and tissue regulation (excluded goods), Faecal Microbiota Transplantation and 2D DataMatrix codes for medicines
Presentation on the background of medicine shortages, definitions, reporting requirements, assessment and management, Section 19A and the compliance framework
Regulatory updates from the TGA Medical Devices Branch - Part 1TGA Australia
Presentation on the review of medicines and medical devices regulation, proposed changes to some definitions and regulation of some products without a medical purpose, reclassification of medical devices (not IVD), Unique Device Identification System and post-market monitoring
Regulatory updates from the TGA Medical Devices Branch - Part 2TGA Australia
The document summarizes proposed regulatory reforms from the Therapeutic Goods Administration (TGA) Medical Devices Branch. It discusses proposed changes to the regulation of software as medical devices, personalized medical devices including 3D printed devices, essential principles, conformity assessment procedures, requirements for devices used in clinical trials, and clarifying requirements for systems and procedure packs. The proposed reforms aim to modernize regulations, increase alignment with international standards, and ensure oversight is risk-based and promotes safety. Public consultations will be held on the proposed changes.
SME Assist: Help to navigate the regulatory mazeTGA Australia
Presentation to provide information on TGA’s SME Assist and what the service offers, details on upcoming SME Assist events and information on where to find more help
TGA webinar: The Good Manufacturing Practice (GMP) Clearance Framework – an o...TGA Australia
The document provides an overview of Australia's Good Manufacturing Practice (GMP) Clearance Framework. It discusses the legislative basis for manufacturing requirements, the roles and activities of the Manufacturing Quality Branch, and the two pathways for obtaining a GMP Clearance - a desk-based assessment through a Mutual Recognition Agreement or Compliance Verification, or an on-site TGA inspection. It also outlines the history of GMP Clearance, recognized authorities through agreements like MRAs, and the MRA assessment pathway.
Presentation: Updates from the Pharmacovigilance and Special Access BranchTGA Australia
This presentation covers using new sources of data in Pharmacovigilance, Pharmacovigilance Inspection Program update, international collaboration activities and Adverse Event Management System.
Presentation: The challenges of regulating direct to consumer digital medical...TGA Australia
The document discusses the challenges of regulating direct-to-consumer digital medical devices. It describes what digital medical devices are, including connected devices, telehealth, apps, and wearables. The Therapeutic Goods Administration (TGA) regulates medical devices in Australia to ensure they are safe and effective. However, digital devices pose new challenges as many are software-based and consumers may not understand their intended medical purpose. The TGA must determine how to appropriately apply existing regulations to these new technologies.
TGA Presentation: Therapeutic Goods Advertising Code (No. 2) 2018TGA Australia
The document provides background information on Australia's Therapeutic Goods Advertising legislation and Code. It discusses key aspects of the legislation including:
- The Therapeutic Goods Act and Regulations set advertising requirements for therapeutic goods. Advertising must also comply with the Australian Consumer Law.
- The Act prohibits off-label promotion and requires pre-approval of medicine ads in certain media. It also places restrictions on advertising certain medical conditions.
- The Therapeutic Goods Advertising Code provides the framework for ensuring advertising is conducted properly and does not mislead consumers. It was recently revised to provide more clarity.
- The Code applies broadly to any advertising of therapeutic goods. It exempts genuine news reporting and ads directed to health
TEST BANK For Community Health Nursing A Canadian Perspective, 5th Edition by...Donc Test
TEST BANK For Community Health Nursing A Canadian Perspective, 5th Edition by Stamler, Verified Chapters 1 - 33, Complete Newest Version Community Health Nursing A Canadian Perspective, 5th Edition by Stamler, Verified Chapters 1 - 33, Complete Newest Version Community Health Nursing A Canadian Perspective, 5th Edition by Stamler Community Health Nursing A Canadian Perspective, 5th Edition TEST BANK by Stamler Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Pdf Chapters Download Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Pdf Download Stuvia Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Study Guide Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Ebook Download Stuvia Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Questions and Answers Quizlet Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Studocu Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Quizlet Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Stuvia Community Health Nursing A Canadian Perspective, 5th Edition Pdf Chapters Download Community Health Nursing A Canadian Perspective, 5th Edition Pdf Download Course Hero Community Health Nursing A Canadian Perspective, 5th Edition Answers Quizlet Community Health Nursing A Canadian Perspective, 5th Edition Ebook Download Course hero Community Health Nursing A Canadian Perspective, 5th Edition Questions and Answers Community Health Nursing A Canadian Perspective, 5th Edition Studocu Community Health Nursing A Canadian Perspective, 5th Edition Quizlet Community Health Nursing A Canadian Perspective, 5th Edition Stuvia Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Pdf Chapters Download Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Pdf Download Stuvia Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Study Guide Questions and Answers Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Ebook Download Stuvia Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Questions Quizlet Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Studocu Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Quizlet Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Stuvia
Integrating Ayurveda into Parkinson’s Management: A Holistic ApproachAyurveda ForAll
Explore the benefits of combining Ayurveda with conventional Parkinson's treatments. Learn how a holistic approach can manage symptoms, enhance well-being, and balance body energies. Discover the steps to safely integrate Ayurvedic practices into your Parkinson’s care plan, including expert guidance on diet, herbal remedies, and lifestyle modifications.
Rasamanikya is a excellent preparation in the field of Rasashastra, it is used in various Kushtha Roga, Shwasa, Vicharchika, Bhagandara, Vatarakta, and Phiranga Roga. In this article Preparation& Comparative analytical profile for both Formulationon i.e Rasamanikya prepared by Kushmanda swarasa & Churnodhaka Shodita Haratala. The study aims to provide insights into the comparative efficacy and analytical aspects of these formulations for enhanced therapeutic outcomes.
Does Over-Masturbation Contribute to Chronic Prostatitis.pptxwalterHu5
In some case, your chronic prostatitis may be related to over-masturbation. Generally, natural medicine Diuretic and Anti-inflammatory Pill can help mee get a cure.
Osteoporosis - Definition , Evaluation and Management .pdfJim Jacob Roy
Osteoporosis is an increasing cause of morbidity among the elderly.
In this document , a brief outline of osteoporosis is given , including the risk factors of osteoporosis fractures , the indications for testing bone mineral density and the management of osteoporosis
Basavarajeeyam is an important text for ayurvedic physician belonging to andhra pradehs. It is a popular compendium in various parts of our country as well as in andhra pradesh. The content of the text was presented in sanskrit and telugu language (Bilingual). One of the most famous book in ayurvedic pharmaceutics and therapeutics. This book contains 25 chapters called as prakaranas. Many rasaoushadis were explained, pioneer of dhatu druti, nadi pareeksha, mutra pareeksha etc. Belongs to the period of 15-16 century. New diseases like upadamsha, phiranga rogas are explained.
Basavarajeeyam is a Sreshta Sangraha grantha (Compiled book ), written by Neelkanta kotturu Basavaraja Virachita. It contains 25 Prakaranas, First 24 Chapters related to Rogas& 25th to Rasadravyas.
Here is the updated list of Top Best Ayurvedic medicine for Gas and Indigestion and those are Gas-O-Go Syp for Dyspepsia | Lavizyme Syrup for Acidity | Yumzyme Hepatoprotective Capsules etc
TGA’s role in ensuring quality complementary medicines
1. TGA’s role in ensuring quality complementary medicines
3 June 2015
Larry Kelly
First Assistant Secretary
Monitoring and Compliance Division, TGA
Complementary Medicines Australia - 2015 Quality Learning Seminar
2. TGA’s role – part of the Commonwealth Department of Health
• Regulates therapeutic goods including prescription, over-the-counter and complementary
medicines, medical devices, biologicals, blood and blood products
• Applies risk-based practices in pre- and post-market phases
• Focuses on safety, efficacy and quality
• We do not make regulatory decisions based on cost or value for money
1TGA’s role in ensuring quality complementary
medicines
3. Risk based regulation of medicines
2TGA’s role in ensuring quality complementary
medicines
4. Regulatory framework for complementary medicines
3TGA’s role in ensuring quality complementary
medicines
RISK FRAMEWORK
5. Regulatory framework for complementary
medicines – Pre-market
• Listed complementary medicines are included in the Australian Register of Therapeutic Goods
(ARTG) via an electronic lodgement process
• Products must be made from a list of ‘safe’ ingredients, with limits on quantities where relevant,
and must not make high-level claims
• Must be made in TGA approved manufacturing facilities
TGA’s role in ensuring quality complementary
medicines
4
6. Regulatory framework for complementary
medicines – Pre-market
• No requirement for sponsor to provide efficacy data prior to lodgement but must certify that efficacy data is
available on request
• Sponsor certifies the information in the application is true and correct
• TGA undertakes random and targeted desk top compliance audits of listed complementary medicines
5TGA’s role in ensuring quality complementary
medicines
7. Regulatory framework for complementary medicines –
Post-market
6http://www.tga.gov.au/about/compliance-framework.htm
9. Ongoing monitoring for compliance
8TGA’s role in ensuring quality complementary
medicines
• Ongoing monitoring detects signals of potential
safety or compliance issues
• Signals are triaged
• Compliance action taken where appropriate
• Monitoring programs may be adjusted as a
result
10. Ongoing monitoring for compliance
• We use a series of ongoing monitoring activities to ensure that regulatory compliance and safety of products
continues after supply
– sponsors are responsible for the performance of their products in the marketplace, and
– sponsors must report serious problems to the TGA in a timely manner
• We monitor the market for signals of potential non-compliance
• A risk-based approach is used to determine the significance of signals and the appropriate regulatory
response
• We apply a proportionate response to non-compliance
9TGA’s role in ensuring quality complementary
medicines
11. Ongoing monitoring for compliance
• Monitoring activities may include:
– random, flagged or targeted reviews of technical and/or clinical information
– laboratory testing for compliance with standards (BP, USP etc)
– inspections of manufacturer’s or sponsor’s records and documentation
– audits of distribution records
– audits of the traceability of raw materials used in the manufacture of therapeutic goods
– trend analysis (refer to http://www.tga.gov.au/about/tga-performance-report.htm)
10TGA’s role in ensuring quality complementary
medicines
12. Compliance action
• We may take corrective action if problems are found, such as:
– sponsors and/or manufacturers not fulfilling their regulatory responsibilities
– Products found to be of unacceptable safety, quality or efficacy
– certifications made in an application are incorrect or no longer correct
• Actions may be batch specific or may be at product level
• Main drivers for regulatory action:
– Public health impact
– Repeat offenders
11TGA’s role in ensuring quality complementary
medicines
13. Compliance action
• We can take a range of action in relation to a compliance matter:
– encouragement/guidance
– warnings
– Imposition of conditions on ARTG entry or manufacturing licence
– Suspension or cancellation of ARTG entry or manufacturing licence
– criminal prosecution/civil penalties
– product recall
– seizure and destruction of unlawful product
• We work with sponsors to achieve compliance where possible
• Details of compliance actions and product recalls are published on our website
12TGA’s role in ensuring quality complementary
medicines
14. Regulatory framework for complementary
medicines
13TGA’s role in ensuring quality complementary
medicines
RISK FRAMEWORK
15. Regulatory framework for complementary medicines – Post-
market
Post-listing activities include:
• desk-based audits of listed medicines
• laboratory testing of products and ingredients for compliance with standards
• surveillance in the marketplace
• monitoring of adverse reactions
• audit of manufacturing sites
• controls for advertising
14TGA’s role in ensuring quality complementary
medicines
16. Regulatory framework for complementary medicines – Post-
market
• Ingredients and Products must comply with BP/EP or USP where a monograph exists
• TGA testing is for compliance with these requirements
• A very small number of complementary medicines are covered by Official monographs
• We also test for the presence of adulterants
15TGA’s role in ensuring quality complementary
medicines
17. Regulatory framework for complementary medicines -
Manufacturing guidance
• TGA requires compliance with the PIC/s Code of Good Manufacturing Practice for Medicinal
Substances
• With industry, TGA has developed interpretive guidelines for the particular requirements of
complementary medicines on:
– Supplier qualification
– Stability testing
– Product Quality Reviews
– Sampling and testing
– Process validation
16TGA’s role in ensuring quality complementary
medicines
18. In conclusion, the key features of the TGA regulatory framework are:
• A risk-based approach is taken to regulation, with different levels of risks for different products.
• Regulation occurs both pre-market and post-market but for listed medicines most regulation is post-market
• Both product risks and compliance risks are regulated.
• There is a focus on fostering voluntary compliance
• Regulatory responses are proportional to the risks to public health
17TGA’s role in ensuring quality complementary
medicines